Menu

Alexion Pharmaceuticals, (ALXN): Q3 2019 Earnings Snapshot

By Toby |
Earnings Update by AlphaStreet

Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) reported third-quarter 2019 earnings of $2.79 per share, vs. $2.47 per share expected.

Revenues grew 23% to $1.26 billion, vs. $1.24 billion expected. Sales of SOLIRIS (eculizumab) came in at $990.5 million, up 12% year-over-year.

Raised FY19 revenue guidance to $4.86 – $4.89 billion vs. prior guidance of $4.75 – $4.8 billion billion.

Adjusted EPS guidance for FY19 raised to a new range of $10.25 – $10.40, vs. earlier guidance of $9.65 – $9.85.

ALXN shares rose 1.7% immediately following the announcement.

Alexion Pharmaceuticals Q3 2019 earnings infographic

Browse through our earnings calendar and get all scheduled earnings announcements, analyst/investor conference and much more!

Advertisement

220 responses to “Alexion Pharmaceuticals, (ALXN): Q3 2019 Earnings Snapshot”

  1. regional

    […]Wonderful story, reckoned we could combine a couple of unrelated data, nevertheless really worth taking a appear, whoa did 1 find out about Mid East has got more problerms at the same time […]

  2. ItMe.Xyz

    […]we prefer to honor numerous other world-wide-web web pages on the net, even when they aren’t linked to us, by linking to them. Underneath are some webpages really worth checking out[…]

  3. dog collar chanel

    […]Wonderful story, reckoned we could combine a couple of unrelated data, nonetheless seriously really worth taking a appear, whoa did one particular understand about Mid East has got far more problerms also […]

Leave a Reply

Top